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Type 2 diabetes (T2D) is characterized by multiple pathophysi-
ological deficits, which collectively foster a state of chronic 
hyperglycemia.1,2 As T2D progresses, patients become increas-
ingly insulin deficient and eventually require more intensive 
therapy, typically including a basal insulin and often a prandial 
insulin. Adherence to more complicated basal–bolus regimens 
may be challenging. These regimens have an increased risk of 
hypoglycemia and weight gain, and both patients and health 
care providers may be reluctant to intensify therapy despite 
being clinically indicated. Even adherent patients with seem-
ingly adequate glycemic control measured by hemoglobin A1C 
(A1c) may experience significant glucose excursions over 24 
hours, at least in part due to elevations in postprandial glucose 
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Abstract
Objective: IDegLira is a novel, fixed-ratio combination of the long-acting basal insulin, insulin degludec, and the long-acting 
glucagon-like peptide-1 analog liraglutide. We studied the effect of IDegLira versus its components on postprandial glucose 
(PPG) in type 2 diabetes.
Methods: In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-
week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or liraglutide. Continuous 
glucose monitoring (CGM) for 72 hours and a meal test were performed.
Results: At week 26, IDegLira produced a significantly greater decrease from baseline in mean PPG increment (normalized 
iAUC0-4h) than insulin degludec (estimated treatment difference [ETD] –12.79 mg/dl [95% CI: –21.08; –4.68], P = .0023) and 
a similar magnitude of decrease as liraglutide (ETD –1.62 mg/dl [95% CI: –10.09; 6.67], P = .70). CGM indicated a greater 
reduction in change from baseline in PPG increment (iAUC0-4h) for IDegLira versus insulin degludec over all 3 main meals 
(ETD –6.13 mg/dl [95% CI: –10.27, –1.98], P = .0047) and similar reductions versus liraglutide (ETD –1.80 mg/dl [95% CI: 
–2.52, 5.95], P = .4122). Insulin secretion ratio and static index were greater for IDegLira versus insulin degludec (P = .048 
and P = .006, respectively) and similar to liraglutide (P = .45 and P = .895, respectively).
Conclusions: Once-daily IDegLira provides significantly better PPG control following a mixed meal test than insulin degludec. 
The improvement is at least partially explained by higher endogenous insulin secretion and improved beta cell function with 
IDegLira. The benefits of liraglutide on PPG control are maintained across all main meals in the combination.
Keywords
diabetes therapy, insulin degludec, liraglutide, postprandial glucose, incretins, combination therapy, quality of glycemic control
390 Journal of Diabetes Science and Technology 10(2)
(PPG). Although it is not yet established that reduction of post-
prandial glycemia alone is sufficient to reduce the risk of vas-
cular disease in people with diabetes, the total amount of time 
spent under conditions of hyperglycemia is an important deter-
minant for development of diabetes complications.3-8 Thus, a 
treatment that helps address both fasting and postprandial con-
trol should be more effective in reducing the amount of time 
spent in the hyperglycemic state.
Accordingly, treatment incorporating several different 
classes of drugs with complementary modes of action may 
be the preferred strategy in T2D.9,10 The combination prod-
uct insulin degludec/liraglutide (IDegLira; Xultophy®, 
Novo Nordisk A/S, Bagsvaerd, Denmark) has been devel-
oped for the treatment of T2D to take clinical advantage of 
the complementary modes of action of its individual compo-
nents, the once-daily basal insulin with long duration of 
action, insulin degludec, and the once-daily, long-acting 
human glucagon-like peptide-1 (GLP-1) analog liraglutide. 
In clinical trials, insulin degludec demonstrated similar 
improvements in A1c to insulin glargine but with fewer epi-
sodes of hypoglycemia, particularly nocturnal episodes, 
across a broad spectrum of patients with diabetes.11 With a 
24-hour duration of action, liraglutide improves glycemic 
control by lowering fasting plasma glucose (FPG) and PPG 
in patients with T2D.12 When liraglutide is used in combina-
tion with basal insulin, improvements in glycemic control 
are achieved without increasing the risk of hypoglycemia 
and weight gain.13-16
The efficacy and safety of IDegLira was demonstrated in 
the DUAL I trial. DUAL I was a 26-week, randomized, 
open-label trial involving 1663 adults with T2D (mean age 
55 ± 10 years, BMI ≤40 kg/m2) with unsatisfactory glycemic 
control (A1c 7-10%) on metformin ± pioglitazone.17 In the 
full population, glycemic control was assessed by A1c, FPG, 
and 9-point self-monitored blood glucose (SMBG) profiles. 
At 26 weeks, A1c with IDegLira was shown to be signifi-
cantly better than insulin degludec (estimated treatment dif-
ference [ETD] –0.47% [95% CI: –0.58; –0.36], P < .0001) 
and superior to liraglutide (ETD –0.64% [95% CI: –0.75; 
–0.53], P < .0001). There was no significant difference in 
FPG reduction between IDegLira and insulin degludec (P = 
.16). However, IDegLira reduced FPG more than liraglutide 
(P < .0001). As assessed by 9-point SMBG profiles, IDegLira 
reduced the PPG increment more than insulin degludec, and 
equally well as liraglutide used alone, both for individual 
meals and across all main meals.17
This preplanned, prospective substudy from DUAL I17 
was conducted to more precisely characterize the postpran-
dial glycemic control provided by IDegLira, in comparison 
with each of its components. Postprandial glycemic control 
was assessed using 2 different approaches: by measuring 
glucose profiles after a single, standardized meal test, where 
we also measured hormone profiles and beta cell function, 
and by measuring interstitial glucose profiles across all 3 
main meals via continuous glucose monitoring (CGM).
Methods
The study reported here involved a subpopulation of 260 
(15.6%) of the original 1663 participants from the DUAL I 
trial, who underwent a standardized meal test. Among the 
substudy participants, 131 were randomized to IDegLira, 64 
to insulin degludec and 65 to liraglutide. Patient recruitment 
and eligibility, treatment, and statistical analyses have been 
described elsewhere.17 The study was conducted in accor-
dance with Declaration of Helsinki18 and Good Clinical 
Practice guidelines.19 Countries invited to participate in this 
substudy (Australia, Finland, France, Germany, Hungary, 
India, Ireland, Italy, Russian Federation, Spain, United 
Kingdom, and United States) were selected based on experi-
ence with the meal test and CGM. Recruitment began May 
23, 2011, and follow-up continued until October 31, 2011.
IDegLira was administered as dose steps, with each step 
containing 1 unit of insulin degludec and 0.036 mg of lira-
glutide. IDegLira was initiated at 10 dose steps (10 units 
insulin degludec plus 0.36 mg liraglutide) and insulin 
degludec was initiated at 10 units. On the basis of prebreak-
fast SMBG measurements (mean of 3 consecutive days), 
IDegLira and insulin degludec doses were titrated stepwise 
twice a week to an FPG target of 72-90 mg/dl; if blood glu-
cose was <72 or >90 mg/dl, the IDegLira dose was decreased 
or increased by ± 2 dose steps, respectively, and the insulin 
degludec dose was decreased or increased by ± 2 units. 
IDegLira could be titrated to a maximum of 50 dose steps (50 
units insulin degludec and 1.8 mg liraglutide), but there was 
no dose limit for insulin degludec. Liraglutide was initiated 
at 0.6 mg/day and increased by 0.6 mg per week, with the 
goal of eventually reaching 1.8 mg/day for all participants in 
this substudy by week 3. All 3 treatments could be adminis-
tered at any time of day as long as the chosen time was used 
consistently. Similar proportions of patients administered 
their treatment in the morning in all 3 arms.
Postprandial Glucose and Hormone Profiles 
During a Standardized Meal Test
The meal test was conducted in the morning after fasting for 
≥8 hours, at baseline and at week 26. Subjects consumed a 
single, standardized, liquid mixed meal containing ~675 cal-
ories with 14.8% protein, 57.0% carbohydrates, 28.2% fat 
(Ensure Plus®, Abbot Laboratories, Columbus, Ohio). Trial 
products and oral antidiabetic drugs (OADs) were withheld 
on the day of the meal test until blood sampling had been 
completed (meal test duration of 4.5-5 hours). Blood sam-
ples for determination of plasma glucose (PG), insulin, 
C-peptide, and glucagon levels were taken at 9 time points in 
relation to the start of the test meal: –10, +15, +30, +45, +60, 
+90, +120, +180, and + 240 minutes.
A central laboratory (Quintiles Limited, Kingston, UK) 
performed laboratory analyses for glucose, insulin, C-peptide, 
and glucagon. Insulin and C-peptide were analyzed in serum 
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using chemiluminescence immunoassay methods. Plasma 
glucagon was measured using the Millipore Glucagon radio-
immunoassay (Ref GL-32K; Millipore, Billerica, MA, USA).
Postprandial Interstitial Glucose Profiles
CGM20 was used to characterize interstitial glucose excur-
sions over a 24-hour period encompassing all 3 main meals, 
at baseline and at week 26. Subjects wore the CGM device 
(iPro1 [United States] and iPro2 [Europe and Australia], 
Medtronic International, Tolochenaz, Switzerland) for a 
minimum of 72 hours for each recording, performed 3-4 
days just before site visits. Subjects were instructed not to 
change their diet, OAD dose, or product treatment dose dur-
ing the 72-hour period.
Statistical Analysis
For data from the standardized meal test, at 26 weeks of 
treatment, the incremental area under the curve from 0 to 4 
hours (iAUC0-4h) for PPG, C-peptide, insulin, and glucagon 
was calculated using the trapezoidal method divided by the 
actual measurement time, using the available valid observa-
tions and the associated actual elapsed time point. AUC end-
points were log-transformed and analyzed separately using 
an ANCOVA model (hereafter the standard ANCOVA 
model), with treatment, country, baseline A1c stratum, and 
previous OAD treatment as fixed factors and the relevant 
log-transformed baseline value used as covariate. The result-
ing AUC provided the (normalized) prandial increment. The 
mean increment for all meals was calculated as the mean of 
all available meal increments.
In addition, beta cell function was assessed by the insulin 
secretion ratio (AUC0-4h insulin/AUC0-4h glucose), which expresses 
the insulin release over the 4-hour postprandial period rela-
tive to the concomitant PG levels; and by the static index, 
which also expresses the meal-derived estimate of the beta 
cell response to a change in glucose, but uses C-peptide lev-
els that are modeled by means of the minimal model.21 Units 
for the insulin secretion ratio and static index are presented 
as described by Breda et al.21
For interstitial glucose, due to technical issues with the 
iPro1 CGM device used in the USA, many of the CGM pro-
files were uploaded without any data (26% data missing and 
lost from uploads at baseline and 50% missing and lost from 
uploads at week 26). In Europe and Australia, where the iPro2 
was used, almost all profiles contained data. Due to the mag-
nitude and nature of missing data from iPro1 (which are 
assumed to be missing completely at random), the CGM 
results are based on observed values rather than imputing 
missing values, such as with using last observation carried for-
ward (LOCF). Mean postprandial increment in interstitial glu-
cose (iAUC0-4h) was calculated as the AUC above the premeal 
value from t = 0 to 4 hours (calculated using the trapezoidal 
method) divided by measurement time. Treatments were com-
pared using the standard ANCOVA model.
Results
Baseline characteristics (Table 1) including A1c and FPG 
were similar to those of the full trial population as previously 
reported.17 The actual (LOCF) mean ± SD dose after 26 
weeks of treatment for 129 patients treated with IDegLira 
was 43 dose steps (43 ± 11 units insulin degludec [range: 
8-50 units] and 1.5 ± 0.4 mg liraglutide [range: 0.3-1.8 mg]; 
60 ± 29 units for 64 patients treated with insulin degludec 
[range: 12-124 units] and 1.8 ± 0.2 mg for 64 patients treated 
with liraglutide [range: 0.6-1.8 mg]). Patient disposition is 
shown in Figure 1.
Glucose and Hormone Profiles during 
Standardized Meal Test
Mean PG levels were similar for all 3 treatment groups at 
baseline, and markedly lower in all treatment groups at 26 
weeks. Comparing treatments, at 26 weeks, mean prandial 
glucose levels for the IDegLira and insulin degludec treatment 
group values were similar (156.0 mg/dl and 163.2 mg/dl, 
respectively), and lower than observed with liraglutide (179.3 
mg/dl) (Figure 2, top row). IDegLira was associated with a 
greater decrease from baseline in mean ± SD PPG increment 
(normalized iAUC0-4h glucose) than insulin degludec (–15.7 ± 
29.7 vs –3.1 ± 35.7 mg/dl; ETD –12.8 mg/dl [95% CI: –21.1; 
–4.68], P = .0023), for a decrease of 21.6% and 4.1%, respec-
tively; there was no significant difference in the reduction 
observed for IDegLira versus liraglutide (–15.7 ± 29.7 vs 
–14.1 ± 29.2 mg/dl; ETD –1.6 mg/dl [95% CI: –10.1; 6.7], 
P = .7000), a decrease of 21.6% and 18.4%, respectively.
The baseline insulin values for normalized iAUC0-4h insulin 
were similar with IDegLira and insulin degludec, and were 
higher than observed with liraglutide at baseline as shown in 
Figure 2 (second row). Changes in postprandial insulin incre-
ment (iAUC0-4h insulin) from baseline to week 26 were 20.6 ± 
127.0 versus –26.7 ± 197.5 pmol/l for IDegLira versus insulin 
degludec, and 20.6 ± 127.0 versus 64.8 ± 119.2 pmol/l for 
IDegLira versus liraglutide. At week 26, ETD for iAUC0-4h insulin 
were 39.3 pmol/l (95% CI: –4.2; 82.8) for IDegLira–insulin 
degludec (P = .0765), representing an increase of 7.7% for 
IDegLira versus a decrease of 12.4% for insulin degludec, and 
–38.5 pmol/l (95% CI: –81.9; 5.0) for IDegLira–liraglutide (P = 
.0827), representing an increase of 7.7% for IDegLira versus an 
increase of 27.4% for liraglutide.
For C-peptide, baseline values for normalized 
iAUC0-4h C-peptide were similar across treatments and increased 
for all treatments at week 26 (Figure 2, third row). Mean 
change in postprandial C-peptide increment (iAUC0-4h 
C-peptide) from baseline to week 26 was 0.11 ± 0.54 versus 0.10 
± 0.60 nmol/l for IDegLira and insulin degludec, respectively, 
and 0.11 ± 0.54 versus 0.25 ± 0.51 nmol/l for IDegLira and 
liraglutide, respectively. At week 26, ETDs for iAUC0-4h 
C-peptide were 0.02 (95% CI: –0.13; 0.18) for IDegLira versus 
insulin degludec (P = .7949), representing an increase of 
8.5% and 8.0%, respectively, and –0.11 (95% CI: –0.26; 0.05) 
392 Journal of Diabetes Science and Technology 10(2)
for IDegLira versus liraglutide (P = .1695), representing 
increases of 8.5% for IDegLira and 21.8% for liraglutide.
For glucagon, normalized iAUC0-4h glucagon responses at 
week 26 appeared similar to baseline, as shown in Figure 2 
(bottom row). Postprandial glucagon increments 
(iAUC0-4h glucagon) were similar for IDegLira and insulin 
degludec (ETD 0.00 pg/ml [95% CI: –3.5; 3.5], P = .9980), 
representing decreases of 33.3% and 32.8%, respectively, 
but significantly lower for IDegLira than for liraglutide 
(ETD –5.4 pg/ml [95% CI: –8.9; –1.9], P = .0029), repre-
senting a decrease of 33.3% for IDegLira versus an increase 
of 11.0% for liraglutide.
Beta Cell Function
At week 26, beta cell function was evaluated by the insulin 
secretion ratio—which, as described above, represents insu-
lin release over the 4-hour postprandial period relative to 
concomitant PG levels—and was higher in the IDegLira 
group compared to the insulin degludec group (33.8 [pmol/
l*min]/[mmol/l*min] vs 25.7 [pmol/l*min]/[mmol/l*min]; 
P = .048) and was similar in the IDegLira and liraglutide 
treatment groups (33.8 and 36.8 [pmol/l*min]/[mmol/l*min], 
respectively; P = .45) (Figure 3, top). Beta cell function as 
Table 1. Baseline Characteristics and End-of-Trial Values (Week 26) for n = 260 Patients Participating in the Standardized Meal Test 
During a Substudy of the DUAL I Trial, by Treatment.
IDegLira Insulin degludec Liraglutide
Full analysis set (n) 131 64 65
Female (n, (%)) 59 (45.0) 28 (43.8) 35 (53.8)
Race (n, (%))
 White 117 (89.3) 59 (92.2) 58 (89.2)
 Black or African American 9 (6.9) 2 (3.1) 3 (4.6)
 Other 5 (3.8) 3 (4.7) 4 (6.2)
Age (years) 54.4 (9.3) 55.0 (8.5) 55.0 (10.3)
Body weight (kg) 92.0 (15.7) 94.1 (18.3) 93.8 (20.1)
Body mass index (kg/m2) 32.5 (4.4) 32.4 (4.5) 32.3 (4.8)
Duration of diabetes (years) 7.5 (5.7) 7.5 (4.9) 8.1 (5.1)
A1c (%) 8.2 (0.9) 8.2 (0.9) 8.3 (1.0)
A1c (mmol/mol) 66 (9.8) 66 (9.8) 67 (10.9)
FPG (mg/dl) 165.8 (41.4) 164.0 (48.6) 165.8 (43.2)
OAD at screening (n (%))
 Metformin 106 (80.9) 51 (79.7) 51 (78.5)
 Metformin + pioglitazone 25 (19.1) 13 (20.3) 13 (20.0)
 Metformin + glimepiride 0 (0.0) 0 (0.0) 1 (1.5)
End of trial values
 A1c (%) 6.3 (1.0) 6.6 (0.8) 7.0 (0.9)
 A1c (mmol/mol) 45 (10.9) 49 (8.7) 53 (9.8)
 FPG (mg/dl) 99.1 (30.6) 97.3 (34.2) 124.3 (34.2)
 Insulin dose (U) 43 (11) 60 (29) NA
 Body weight (kg) 91.6 (15.7) 95.7 (19.5) 91.4 (20.5)
For this substudy, baseline characteristics as well as end of trial values in A1c and FPG corresponded closely with the full trial population.17 Full analysis set. 
Data are mean (SD), unless otherwise noted. FPG, fasting plasma glucose; IDegLira, insulin degludec/liraglutide combination; OAD, oral antidiabetic drug.
Figure 1. Patient disposition. FAS, full analysis set; PPS,  
per-protocol set; SAS, safety analysis set.
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Figure 2. Mean plasma glucose (top row), mean serum insulin (second row), mean serum C-peptide (third row), and mean plasma 
glucagon (bottom row) profiles, for 260 patients with type 2 diabetes participating in a standardized meal test as part of the DUAL I trial, 
by treatment. IDeg, insulin degludec; IDegLira, insulin degludec/liraglutide combination; Lira, liraglutide. Labels for vertical axes carry 
through for all panels in a row.
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Figure 4. Mean postprandial interstitial glucose profiles after 
breakfast, lunch, and dinner, measured using CGM, in a subgroup 
of 260 patients with type 2 diabetes participating in the DUAL 
I trial, at baseline (upper panel) and week 26 (lower panel), 
by treatment. Last observation carried forward was used to 
impute missing data. Although all 260 patients (full analysis set) 
were included in the analysis, data were not available at all time 
points at every meal for each patient. See Figure 1 for patient 
disposition. CGM, continuous glucose monitoring, based on 
observed rather than estimated values; IDeg, insulin degludec; 
IDegLira, insulin degludec/liraglutide combination; Lira, liraglutide.
further evaluated using the static index was significantly 
higher for IDegLira versus insulin degludec (0.120 [nmol/
min]/[mmol/l and 0.090 [nmol/min]/[mmol/l], respectively, 
P = .006) and similar in the IDegLira and liraglutide treat-
ment groups (0.120 and 0.119 [nmol/min]/[mmol/l], respec-
tively, P = .895) (Figure 3, bottom).
Interstitial Glucose Profiles Using CGM
With respect to observed change from baseline 
(iAUC0-4h glucose) for interstitial glucose following individual 
meals, there was a greater reduction for IDegLira versus insu-
lin degludec at breakfast (ETD –6.7 mg/dl [95% CI: –13.0; 
–0.4], P = .0373) and evening meal (ETD –7.4 mg/dl [95% 
CI: –13.2; –1.6], P = .0130); the lunch value was numerically 
lower but not significantly different for IDegLira and insulin 
degludec (ETD –3.6 mg/dl [95% CI: –9.9; 2.5], P = .2430). 
There were no differences at any meal between IDegLira and 
liraglutide (Figure 4). Observed change from baseline in post-
prandial interstitial glucose increment (iAUC0-4h glucose) aver-
aged over all 3 main meals was also significantly different for 
IDegLira versus insulin degludec (ETD –6.1 mg/dl [95% CI: 
–10.3; –2.0], P = .0047) but similar for IDegLira and liraglu-
tide (ETD –1.8 mg/dl [95% CI: –2.5; 6.0], P = .4122).
Safety
As previously reported for all patients participating in 
DUAL I,17 IDegLira was well tolerated, and the profile of 
adverse events (AEs) reflected those of the components insu-
lin degludec and liraglutide. In this substudy population, 
serious AEs were reported for a minority of subjects across 
treatment groups (n = 1/130 [0.8%] for IDegLira, n = 2/64 
[3.1%] for insulin degludec, n = 2/65 [3.1%] for liraglutide) 
and deemed unlikely to be related to trial products. The num-
ber of confirmed hypoglycemic events (ie, episodes con-
firmed by a PG of <56 mg/dl and severe episodes) per 
patient-year was 1.33 for IDegLira, 3.38 for insulin degludec, 
and 0.22 for liraglutide. No clustering or unexpected patterns 
in the reported AEs were observed, and frequencies were 
generally similar to the full population17 (Table 2).
Discussion
In this preplanned, prospective substudy of 260 subjects par-
ticipating in DUAL I, using more detailed PPG assessments 
(CGM plus meal test) compared with the main trial, which 
Figure 3. Insulin secretion to glucose ratio (top) and beta cell 
function (bottom) at week 26 for a subset of patients (n = 260) 
with type 2 diabetes participating in a standardized meal test 
during the DUAL I trial. IDeg, insulin degludec; IDegLira, insulin 
degludec/liraglutide combination; Lira, liraglutide. Top panel: 
Insulin secretion ratio,8 which expresses the insulin release over 
the 4-hour postprandial period adjusted for the concomitant 
plasma glucose levels, was calculated as AUC0-4h insulin /  
AUC0-4h glucose. Bottom panel: Estimates of overall static insulin 
secretion during the meal test were calculated as the static 
index.21 The static index also expresses the meal-derived 
estimate of the beta cell response to a change in glucose, but 
uses C-peptide levels that are analyzed using the minimal model.21 
Units for the insulin secretion ratio and static index are presented 
as described by Breda et al.21
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reported SMBG findings, we show that the effect of liraglu-
tide on postprandial glycemic control was preserved when 
used in conjunction with insulin degludec in the combination 
product, IDegLira. This is demonstrated by lower blood glu-
cose levels with IDegLira during a standardized meal test 
following a single meal and by improved interstitial glucose 
profiles measured using CGM over 3 main meals. Compared 
to insulin degludec alone, which demonstrated a 4.1% 
decrease from baseline in PPG increment, the decrease with 
IDegLira was 21.6% versus 18.4% with liraglutide. These 
data are consistent with the 9-point SMBG profile results 
from the full analysis set for all (n = 1663) subjects in the 
main trial, which showed a greater reduction in PPG incre-
ment for IDegLira versus insulin degludec for each main 
meal as well as across all 3 meals, and a similar reduction 
compared to liraglutide used alone.17 These results are con-
sistent with those from a study using a standardized meal 
test, at which both absolute and incremental PPG were 
reduced for liraglutide versus placebo.22 In this substudy (as 
in the main trial population), the more gradual titration with 
IDegLira was associated with a reduced incidence of gastro-
intestinal side effects compared to liraglutide alone.
One of the pathophysiological deficits in T2D is chronic 
hyperglucagonemia during fasting and postprandial states.23 
Liraglutide, like other GLP-1 analogs, has a stimulating 
effect on insulin secretion and an inhibitory effect on gluca-
gon secretion, both in a glucose-dependent manner.12 In this 
substudy, the postprandial glucagon response was similar in 
the IDegLira and insulin degludec groups. The glucagon 
response for IDegLira was statistically significantly lower 
compared to liraglutide, which may explain part of the glyce-
mic superiority. However, the underlying mechanism for the 
improved PPG control with IDegLira versus insulin degludec 
observed in this substudy seems to be a stimulatory effect on 
endogenous insulin secretion, rather than enhanced glucagon 
suppression (since glucagon responses were similar). This 
notion is supported by indices of beta cell function (such as 
insulin secretion ratio and static index), which were improved 
for IDegLira versus insulin degludec but were similar 
compared with liraglutide at 26 weeks. The reason for the 
difference in glucagon responses between IDegLira and lira-
glutide could be the combination of 2 potential inhibitors of 
glucagon secretion in IDegLira. However, the precise inter-
action between the 2 cannot be determined from these exper-
iments because of the varying dosing of the individual 
components in the 3 groups. Interestingly, analysis of the 
data from the placebo-controlled LIBRA trial indicated that 
the postprandial glucagonostatic effect of liraglutide 
observed after short-term treatment was lost with chronic 
administration in patients with a short duration of diabetes.24 
However, the overall glycemic effects on insulin secretion, 
C-peptide response and reduction of glycemic excursion 
were accompanied with an expected improvement of glyce-
mic control (as assessed by A1c and 2-hour glucose) in line 
with the well-established glycemic efficacy of liraglutide. 
More trials are needed to further explore these findings.
Demonstrating the PPG-lowering effect of liraglutide 
(alone or as part of IDegLira) after all meals and after indi-
vidual meals throughout the day, in conjunction with showing 
indices of improved beta cell function (ie, static index and 
insulin secretion ratio), reinforce results previously reported 
using SMBG profiles.17 The long duration of action of liraglu-
tide (half-life 11-15 hours) contributes to blood glucose lower-
ing across all main meals when administered once daily,25 as 
opposed to short-acting GLP-1 receptor agonists, including 
exenatide (half-life 2.4 hours26) and lixisenatide (half-life 2-3 
hours27) which, because of their rapid elimination, primarily 
target the meal immediately following product administration. 
Clinically, these results have implications for the total time 
spent under conditions of hyperglycemia, a known risk factor 
for the development of diabetes complications.3 The reduction 
of the extent and duration of hyperglycemia across all meals 
combined with the concomitant reduction of FPG provided by 
the combined action of the components, liraglutide and insulin 
degludec, provides a greater opportunity to improve the over-
all glycemic control.
This study focuses on the PPG control observed with 
IDegLira compared to each of the monocomponents (insulin 
Table 2. Treatment-Emergent Adverse Events That Occurred in at Least 5% of Patients in Any Treatment Group (or in ≥1% of 
Patients for Increased Lipase) for 260 Patients Participating in a Preplanned Substudy of the DUAL I Trial, by Treatment.
IDegLira (n = 130)
Insulin degludec  
(n = 64) Liraglutide (n = 65)
n (%) Rate n (%) Rate n (%) Rate
Nausea 10 (7.7) 17.4 1 (1.6) 3.2 10 (15.4) 44.7
Diarrhea 8 (6.2) 14.3 4 (6.3) 12.6 7 (10.8) 25.5
Vomiting 4 (3.1) 7.9 0 (0) 0.0 5 (7.7) 16.0
Headache 12 (9.2) 23.8 6 (9.4) 44.2 9 (13.8) 60.7
Nasopharyngitis 16 (12.3) 34.9 5 (7.8) 18.9 7 (10.8) 22.3
Increased lipase concentrationa 6 (4.6) 9.5 3 (4.7) 9.5 3 (4.6) 12.8
Decreased appetite 5 (3.8) 7.9 0 (0) 0.0 4 (6.2) 12.8
Safety analysis set; n, number of subjects; rate, per 100 person-years exposure.
aElevated lipase, 3× upper limit of normal.
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degludec and liraglutide) and reports results using both CGM 
and a meal test. Due to the maintained benefits of liraglutide 
when used in a combination product with insulin degludec, 
IDegLira provides significantly better postprandial glycemic 
control following a mixed meal test than insulin degludec, 
which is at least partially explained by a higher endogenous 
insulin secretion and improved beta cell function with 
IDegLira. Because of the long duration of action of the lira-
glutide component of IDegLira, the effect on PPG is evident 
across all main meals, and IDegLira is able to achieve tighter 
glycemic control compared with either insulin degludec or 
liraglutide used alone.
Conclusions
The improved control of PPG described for patients in this 
substudy is consistent with results from the full analysis set 
from the main DUAL I trial, which showed 81% of patients 
using IDegLira achieved A1c <7.0%, compared with 65% of 
patients using insulin degludec and 60% using liraglutide 
(both P < .0001 vs IDegLira).17 That analysis also reported 
that more patients using IDegLira achieved glucose targets 
without increasing hypoglycemia and/or weight gain, com-
pared to insulin degludec. Improved tolerability of IDegLira 
compared to its monocomponents, in conjunction with 
improved glycemic control during fasting as well as after 
meals, and the convenience of administering both drugs in a 
single injection, should be appealing to patients and provid-
ers alike.
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